Sernova-HemAcure Consortium to Present Achievements in Development of a Regenerative Medicine Approach to Treat Hemophilia A

  Sernova Corp., a regenerative medicine company, announces that Dr. Philip Toleikis, Sernova’s President and CEO, along with the additional Horizon 2020 HemAcure Consortium Leaders, will present an overview of key achievements in developing a novel cell-based therapy for the treatment of Hemophilia A, in a publicly accessible webinar. The webinar will include an introduction…